📢 New insights from PEACE-1

This post-hoc analysis examines how adjusting for abiraterone-prednisone cross-over impacts survival outcomes in de novo mCSPC.

A key step in refining trial interpretation.

🔗 Read more: www.eortc.org/publications/

#PEACE1 #ProstateCancer #ClinicalTrials #EORTC

PEACE-1: Radiotherapy + abiraterone improves rPFS in low-volume de novo mCSPC but not OS. It reduces serious genitourinary events without increasing toxicity. A promising addition to standard care #ProstateCancer #Oncology #PEACE1 @oncoalert.bsky.social @bossial.bsky.social @apccc.bsky.social